(Q38102589)

28 August 2017

title

Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre (English)

1 reference

28 August 2017

0 references

1 reference

1 reference

1 reference

A O'Connor

1

1 reference

28 August 2017

I Taneike

2

1 reference

28 August 2017

A Nami

3

1 reference

28 August 2017

N Fitzgerald

4

1 reference

28 August 2017

B Ryan

5

1 reference

28 August 2017

N Breslin

6

1 reference

28 August 2017

H O'Connor

7

1 reference

28 August 2017

D McNamara

8

1 reference

28 August 2017

P Murphy

9

1 reference

28 August 2017

C O'Morain

10

1 reference

28 August 2017

publication date

27 April 2013

1 reference

Irish Journal of Medical Science

28 August 2017

published in

1 reference

28 August 2017

volume

182

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

693-695

1 reference

https://scigraph.springernature.com/pub.10.1007/s11845-013-0957-3

28 August 2017

exact match

0 references

cites work

Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

High level of antimicrobial resistance in French Helicobacter pylori isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Frequency and molecular characteristics of ciprofloxacin- and rifampicin-resistant Helicobacter pylori from gastric infections in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Quinolone resistance in Helicobacter pylori isolates in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11845-013-0957-3

Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain

21 January 2018

1 reference

12 December 2020

Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.

1 reference

12 December 2020

Worldwide H. pylori antibiotic resistance: a systematic review.

1 reference

12 December 2020

Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-2005).

1 reference

12 December 2020

Second-Line Rescue Therapy With Levofloxacin After H. pylori Treatment Failure: A Spanish Multicenter Study of 300 Patients

1 reference

12 December 2020

Re-treatment after Helicobacter pylori eradication failure.

1 reference

12 December 2020

10.1007/S11845-013-0957-3

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1034850393

0 references

1 reference